The outcome of hyperbaric oxygen therapy versus core decompression in the non-traumatic avascular necrosis of the femoral head: Retrospective Cohort Study.
Avascular osteonecrosis (AVN)
Core decompression
Femur head
Hyperbaric oxygen therapy (HBO)
Oxford hip score (OHS)
SF 12
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
12
2020
revised:
22
01
2021
accepted:
22
01
2021
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Core decompression (CD) has been used in the treatment of pre-collapse stages avascular necrosis (AVN) with good results. Hyperbaric oygen therapy (HBO) was used as a non-invasive treatment for pre-collapse stages osteonecrosis with favorable results. This study aimed to compare the outcomes of HBO versus CD in stage II of non-traumatic AVN of the femoral head. Data were collected retrospectively for patients with non-traumatic AVN of the femoral head that was confirmed by MRI and underwent HBO or CD between January 2010 and December 2018, with a minimum follow-up of 12 months. Oxford Hip Score (OHS), radiographic progression, and Short-Form 12(SF12) were used to assess the outcomes. Nineteen patients with 23 stage II AVN of the femoral head were included, 12 (52.2%) in CD, and 11 (47.8%) in the HBO group with an average follow-up of 34.2 ± 18.4 months.66.7% of patients in CD and 81.8% in the HBO group achieved satisfactory hip function outcome with statistically significant mean Oxford Hip Score (35.8 ± 6.7 and 35.5 ± 5.1) (P 0.009 & .003) respectively.No statistical difference of OHS and SF12 (PCS &MCS) was found between the two groups (P 0.202, 0.128 & .670 respectively).Eight (34.7%) cases progressed to a higher radiological stage at one year follow-up. The rate of progression was not statistically significant between both groups (P 0.469) with no statistical difference of OHS and SF12 (PCS & MCS) in the progressed group (P 0.747, 0.648 & 0.416) respectively. This study showed that the HBO is promising and as effective as CD in the treatment of non-traumatic pre-collapsed AVN of the femoral head. Hence, HBO could be used as an alternative non-invasive treatment option.
Sections du résumé
BACKGROUND
BACKGROUND
Core decompression (CD) has been used in the treatment of pre-collapse stages avascular necrosis (AVN) with good results. Hyperbaric oygen therapy (HBO) was used as a non-invasive treatment for pre-collapse stages osteonecrosis with favorable results. This study aimed to compare the outcomes of HBO versus CD in stage II of non-traumatic AVN of the femoral head.
METHODS
METHODS
Data were collected retrospectively for patients with non-traumatic AVN of the femoral head that was confirmed by MRI and underwent HBO or CD between January 2010 and December 2018, with a minimum follow-up of 12 months. Oxford Hip Score (OHS), radiographic progression, and Short-Form 12(SF12) were used to assess the outcomes.
RESULTS
RESULTS
Nineteen patients with 23 stage II AVN of the femoral head were included, 12 (52.2%) in CD, and 11 (47.8%) in the HBO group with an average follow-up of 34.2 ± 18.4 months.66.7% of patients in CD and 81.8% in the HBO group achieved satisfactory hip function outcome with statistically significant mean Oxford Hip Score (35.8 ± 6.7 and 35.5 ± 5.1) (P 0.009 & .003) respectively.No statistical difference of OHS and SF12 (PCS &MCS) was found between the two groups (P 0.202, 0.128 & .670 respectively).Eight (34.7%) cases progressed to a higher radiological stage at one year follow-up. The rate of progression was not statistically significant between both groups (P 0.469) with no statistical difference of OHS and SF12 (PCS & MCS) in the progressed group (P 0.747, 0.648 & 0.416) respectively.
CONCLUSION
CONCLUSIONS
This study showed that the HBO is promising and as effective as CD in the treatment of non-traumatic pre-collapsed AVN of the femoral head. Hence, HBO could be used as an alternative non-invasive treatment option.
Identifiants
pubmed: 33643644
doi: 10.1016/j.amsu.2021.01.084
pii: S2049-0801(21)00085-6
pmc: PMC7889431
doi:
Types de publication
Journal Article
Langues
eng
Pagination
450-454Informations de copyright
© 2021 The Authors.
Références
J Bone Joint Surg Br. 2008 Jul;90(7):852-7
pubmed: 18591591
J Bone Joint Surg Am. 2003 Jun;85(6):987-93
pubmed: 12783992
J Bone Joint Surg Am. 1995 May;77(5):674-80
pubmed: 7744892
Am J Orthop (Belle Mead NJ). 2000 Mar;29(3):187-94
pubmed: 10746469
N Engl J Med. 1992 May 28;326(22):1473-9
pubmed: 1574093
Orthopedics. 2015 Mar;38(3):e200-5
pubmed: 25760507
J Orthop Surg Res. 2019 Sep 11;14(1):306
pubmed: 31511030
Int J Surg. 2019 Dec;72:156-165
pubmed: 31704426
J Bone Joint Surg Br. 1995 Jan;77(1):34-41
pubmed: 7822393
Undersea Hyperb Med. 2017 Nov-Dec;44(6):497-508
pubmed: 29281187
J Bone Joint Surg Br. 1990 May;72(3):387-90
pubmed: 2341433
J Bone Joint Surg Br. 1991 Jan;73(1):68-72
pubmed: 1991778
Int Orthop. 2001;24(6):316-8
pubmed: 11294420
Eur J Orthop Surg Traumatol. 2020 Feb;30(2):193-197
pubmed: 31538269
J Bone Joint Surg Am. 1998 Sep;80(9):1270-5
pubmed: 9759810
J Bone Joint Surg Am. 2007 Jun;89(6):1194-204
pubmed: 17545421
Clin Orthop Relat Res. 2008 May;466(5):1133-40
pubmed: 18330663
Curr Rev Musculoskelet Med. 2015 Sep;8(3):201-9
pubmed: 26142896
J Bone Joint Surg Br. 2003 Apr;85(3):371-5
pubmed: 12729112
Clin Orthop Relat Res. 2001 May;(386):71-8
pubmed: 11347851
Orthopade. 2017 May;46(5):440-446
pubmed: 27928615
Clin Orthop Relat Res. 2008 May;466(5):1093-103
pubmed: 18392909
Scand J Plast Reconstr Surg Hand Surg. 1988;22(1):31-9
pubmed: 3387922
Clin Orthop Relat Res. 1988 Jun;(231):51-61
pubmed: 3286078
Int Orthop. 2016 Sep;40(9):1827-34
pubmed: 26739599
J Bone Joint Surg Am. 1999 Feb;81(2):200-9
pubmed: 10073583
J Bone Joint Surg Br. 1995 Jan;77(1):42-9
pubmed: 7822394
Int Orthop. 2002;26(1):31-5
pubmed: 11954846
Hip Int. 2014 Jan-Feb;24(1):5-13
pubmed: 24062224
J Bone Joint Surg Br. 1985 Jan;67(1):3-9
pubmed: 3155745